ArticlePloS one2026
Maternal and neonatal outcomes following SARS-CoV-2 infection in an unvaccinated pregnant cohort: A trimester-specific analysis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse pregnancy outcomes are significant public health issues in developing countries. This study aims to evaluate the trimester-specific impact of COVID-19 infection on maternal and neonatal outcomes in a cohort of unvaccinated Iranian women. A multi-center cross-sectional study was conducted between March 21, 2020, and March 21, 2021, involving 217 unvaccinated pregnant women with RT-PCR-confirmed SARS-CoV-2 infection who delivered in hospitals across three counties in Northwest Iran. Participants were stratified by the trimester of COVID-19 diagnosis: first (n = 20), second (n = 87), and third (n = 110). Data on demographics, as well as maternal, obstetric, and neonatal outcomes, were extracted from the National Health System. Statistical analyses included ANOVA, Chi-square, Fisher's exact and Kruskal-Wallis tests, with post-hoc Bonferroni corrections. A significant association was found between the trimester of infection and the rate of PTB (p = 0.028). Women infected in the third trimester had a substantially higher PTB rate (26.4%) compared to those infected in the second (11.5%) and first (15.0%) trimesters. Neonatal outcomes also varied significantly; APGAR scores at 1 and 5 minutes were lowest in the third-trimester infection group (8.16 ± 0.78 and 8.39 ± 0.80, respectively) compared to the first (9.08 ± 0.88 and 9.03 ± 0.90) and second (8.45 ± 0.71 and 8.79 ± 0.83) trimesters (p < 0.001 for both). Fever was significantly more prevalent in the third trimester (33.6%) than in the first (10.0%, p = 0.013). No vertical transmission or neonatal deaths were recorded. This study demonstrates a clear trimester-specific risk gradient for SARS-CoV-2 infection in unvaccinated pregnant women. Infection during the third trimester was associated with a significantly increased odds of PTB and lower neonatal APGAR scores(1,5). These findings underscore the critical vulnerability of late pregnancy to COVID-19 complications and highlight the importance of trimester-specific vigilance, enhanced antenatal surveillance, and robust vaccination advocacy for pregnant women.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.